Oculis Holding AG OCS

NAS: OCS | ISIN: CH1242303498 12/11/2024

14,99 USD (-6,25%)

(-6,25%) 12/11/2024

Grafiek Oculis Holding AG

Grafiek Oculis Holding AG

1 dag1d -6,25%
1 week1w -11,25%
1 maand1m 2,67%
3 maanden3m 30,92%
6 maanden6m 24,19%
1 jaar1j 52,96%
5 jaar5j 37,65%

Oculis Holding AG in het nieuws

Toon enkel gratis nieuws

7 november 2024 · Oculis Reports Q3 2024 Financial Results and Provides Company Updates · Persbericht

21 oktober 2024 · Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees · Persbericht

2 oktober 2024 · Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer · Persbericht

27 augustus 2024 · Oculis Publishes Consolidated Q2 Financial Statements and MD&A · Persbericht

27 augustus 2024 · Oculis Reports Q2 Financial Results and Provides Recent Company Update · Persbericht

15 augustus 2024 · Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer · Persbericht

10 juni 2024 · Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy · Persbericht

4 juni 2024 · Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities · Persbericht

30 mei 2024 · Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board · Persbericht

17 mei 2024 · Oculis updates share capital for its existing at-the-market offering program · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe